Latest News and Press Releases

Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and...

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in...

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in...

48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened...

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and...

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce...

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and...

Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) --...

Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful...